Personalized treatment for cancer with genetic fingerprints
 
Geneva:
+4122 840 33 34
 
Moscow:
+7(903)720 80 57

Personalizing cancer treatment with genetic fingerprint

Date: 30/06/2015
Last edited: 14/07/2015

Not all cancers are equally lethal: cancer in your prostate means a longer survival rate than a malignancy in your brain, for example. But even prostate cancer comes in multiple flavors ranging from manageable to very bad. By analyzing the mutated genome of a tumor, doctors can now pinpoint whether a cancer is sensitive to a certain chemotherapy, or one that doesn’t respond at all to current treatments. Knowing the subtype might mean jumping directly to a clinical trial that could save your life.

Cancer is a disease of the genome. It arises when genes involved in promoting or suppressing cell growth sustain mutations that disturb the normal stop and go signals. There are more than 100 different types of cancer, most of which derive their names and current treatment based on their tissue of origin—breast, colon, or brain, for example. But because of advances in DNA sequencing and analysis, that soon may be about to change.

A new method to take the DNA fingerprint of individual cancer cells is uncovering the true extent of cancer’s genetic diversity. A single cancer cell may help oncologists anticipate tumor growth. A genetic “fingerprint” taken from a cancerous cell can reveal the extent of the cancer’s genetic diversity — its “family tree.” By highlighting key mutations, the method could help doctors develop more effective, personalized therapies.

There is a huge potential to identify key genomic changes shared by certain subsets of tumors, regardless of where they arise in the body. Such information is vital to our efforts to develop more individualized approaches for helping people with cancer—called personalized medicine, or precision medicine. For example, if a patient’s tumor has a genomic fingerprint that indicates it is likely to spread to other areas of the body, or metastasize, doctors may suggest a more aggressive treatment strategy than they would for someone whose tumor had a different profile.

Genomic information might also help us figure out if a drug originally approved for use in one type of cancer might be useful in treating other types. For example, if a drug works for colon cancer, it might also work for a lung cancer with a similar genetic fingerprint.

Comments
Articles
Patient registration form
Topics
Examination Incorpore
age management
Anti-aging
prevention
weight management
detoxification
weight loss
nutrition
oncology
cancer
allergy
dermatology
skin
oncology treatment
diagnosis
cardiology
heavy metal
immunology
check-up
Fertility
cosmetology
skincare
stem cells
Genetics
Blood pressure
DNA
gynecology
pain
liver detox
heart MRI
Examination partner centres
infertility
Allergology
chelation
covid19
liver
urology
Allergology treatment
gastroenterology
Sleep
tinnitus
probiotics
pregnancy
joints
radiology
headache
Hepatitis C
Apnea
NAD+
obstetrics
mesotherapy
rehabilitation
arsenic
candida
andropause
immune system
neurology
breast cancer
immunotherapy
research
PRP
menopause
rhesus factor
pancreas
knee
oncoloy
propofole
magnesium
hand
cellulite
nephrology
R-loops
abdominal pain
migraine
reconstruction
erectile dysfunction
diet
Omega-3
hormones
hip
shoulder
telomere
obstertics
blood test
general surgery
back pain
colonoscopy
mercury
flu
mastectomy
regeneration
water
Treatment programs
kidney
proctology
cellmen
reflexology
hyaluronic acid
acnea
oral checkup
pomegranate
cellcosmet
sexuality
gastroscopy
migraines
dermatitis
liquid biopsy
rheumatology
vitamin K
anti-aging
gastritis
chronic headaches
orthopedics
food
preventiion
ulcer
endocrinology
Дерматология
vitamin b12
herniated disc
endometriosis
digestion
stress
intestinal flora
beauty
brain surgery awake
acne
ophthalmology
depression
exercise
beau-rivage
nutrigenomics
psoriasis
narcosis
LED therapy
flu vaccine
plastic surgery
iron
sports
excimer laser
lungs
food intolerances
second opinion
cholesterol
light therapy
biopsy
pneumology
mammography
diabetes
sugar